CN106520866A - Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene - Google Patents
Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene Download PDFInfo
- Publication number
- CN106520866A CN106520866A CN201611146639.6A CN201611146639A CN106520866A CN 106520866 A CN106520866 A CN 106520866A CN 201611146639 A CN201611146639 A CN 201611146639A CN 106520866 A CN106520866 A CN 106520866A
- Authority
- CN
- China
- Prior art keywords
- sace
- erythromycin
- gene
- strain
- red
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 94
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 57
- 229960003276 erythromycin Drugs 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 20
- 241000187559 Saccharopolyspora erythraea Species 0.000 title abstract 2
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 claims abstract description 17
- 229940098008 erythrocin Drugs 0.000 claims abstract description 17
- 238000009776 industrial production Methods 0.000 claims abstract description 10
- 230000001580 bacterial effect Effects 0.000 claims description 28
- 238000000855 fermentation Methods 0.000 claims description 12
- 230000004151 fermentation Effects 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000001131 transforming effect Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000013459 approach Methods 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 abstract description 13
- 230000037430 deletion Effects 0.000 abstract description 13
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 238000013518 transcription Methods 0.000 abstract description 3
- 230000035897 transcription Effects 0.000 abstract description 3
- 241000187560 Saccharopolyspora Species 0.000 abstract 1
- 229930006677 Erythromycin A Natural products 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000001938 protoplast Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002028 Biomass Substances 0.000 description 4
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930188070 thiostrepton Natural products 0.000 description 4
- 229940063214 thiostrepton Drugs 0.000 description 4
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 4
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 description 3
- 229950006334 apramycin Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DZCOSWPAQGXWKC-TZIZHKBZSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3-(hydroxymethyl)-5,7,9,11,13-pentamethyl-oxacyclotetradecane Chemical compound O([C@@H]1[C@@H](CO)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 DZCOSWPAQGXWKC-TZIZHKBZSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical class N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- MWFRKHPRXPSWNT-UHFFFAOYSA-N Erythromycin-C Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C(C)C1OC1CC(C)(O)C(O)C(C)O1 MWFRKHPRXPSWNT-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- CLQUUOKNEOQBSW-KEGKUKQHSA-N erythromycin D Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 CLQUUOKNEOQBSW-KEGKUKQHSA-N 0.000 description 2
- PRUSTPADOGZAML-UHFFFAOYSA-N erythromycin E Natural products O1C2C(C)C(OC3C(C(CC(C)O3)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C2COC21CC(C)(OC)C(O)C(C)O2 PRUSTPADOGZAML-UHFFFAOYSA-N 0.000 description 2
- PRUSTPADOGZAML-LMXGZOGMSA-N erythromycin E Chemical compound C([C@H]1C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@@H](C)[C@@H]1O1)(C)O)CC)O[C@]21C[C@@](C)(OC)[C@@H](O)[C@H](C)O2 PRUSTPADOGZAML-LMXGZOGMSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950002013 berythromycin Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- IDRYSCOQVVUBIJ-PPGFLMPOSA-N erythromycin B Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 IDRYSCOQVVUBIJ-PPGFLMPOSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000009655 industrial fermentation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940083668 ketek Drugs 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000009055 negative regulation of biosynthetic process Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008723 osmotic stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229930001119 polyketide Natural products 0.000 description 1
- 150000003881 polyketide derivatives Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
- C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a saccharopolyspora erythraea by modifyingSACE_3980A method for increasing the output of erythrocin by gene engineering of the deletion of the TetR family transcription regulation gene in saccharopolyspora erythraeaSACE_3980The erythromycin high-yield engineering strain is obtained, and the yield can be greatly improved by fermenting and producing the erythromycin by using the obtained strain, thereby providing a new technical support for improving the yield of the erythromycin in industrial production.
Description
Technical field
The present invention relates to gene engineering technology field, and in particular to a kind of by transforming the red mycete SACE_3980 of sugared many spores
The method that gene improves yield of erythrocin.
Background technology
Erythromycin is produced by the red mycete cometabolism of sugared many spores, belongs to typical polyketide, and its component includes
Erythromycin A (Er-A), berythromycin (Er-B), Erythromycin C (Er-C), Erythromycin D (Er-D), Erythromycin E (Er-E) and erythromycin
F (Er-F) etc..Such antibiosis have broad-spectrum antibacterial action, and its antimicrobial spectrum is similar to penicillin, has stronger to gram positive bacteria
Inhibitory action.Clinically wide variety of in erythromycin each component is Erythromycin A, its bacteriostatic activity highest, and erythromycin system
Row chemical derivative (clarithromycin, Azithromycin, Roxithromycin, Ketek etc.) is also widely used for treating infectious disease
Disease, the annual sales volume of erythromycin and its derivant reach tens billion of dollars.
Erythromycin has important function in field of medicaments, but its yield still has much room for improvement.Traditional optimization of fermentation conditions is improved
The method of Erythromycin A yield is time-consuming and uneconomical, is not suitable for extensively application.And by engineered method, it is red in sugared many spores
Increase the copy number of synthetic gene in mycete chromosome, or transform controlling gene to obtain erythromycin by the method for gene knockout
Superior strain, has good prospect.
The report erythromycin high yield such as Rodriguez in 2003 is mainly due to its controlling gene, rather than synthetic gene, more
Make us that research emphasis are turned to regulator gene.2005, Ramos etc. was standard by original with sequence similarity, 26S Proteasome Structure and Function
Core biology transcription regulator be divided into LysR, AraC/XylS, TetR, LuxR, LacI, ArsR, IcIR, MerR, AsnC, MarR,
NtrC (EBP), OmpR, DeoR, Cold shock, GntR and Crp totally 16 families.Wherein TetR families controlling gene is in DNA
There are the conservative of height, wide participation regulation and control multi-drug resistance, antibiotic synthesis, osmotic stress reaction etc. raw on binding structural domain
Thing activity.Various TetR families transcription regulators for participating in antibiotic or streptomycete Morphological Differentiation are reported in recent years, such as
SCO1712, SAV151, SAV576, jadY, atrA etc., imply TetR families controlling gene in secondary metabolism of Streptomyces and resist
Importance in raw element biosynthesiss.There are 101 TetR family genes in the red mycete full-length genome of many spores of sugar, however it is many with regard to sugar
Still seldom, the only participation of report regulates and controls the red mycete shape of sugared many spores to the red mycete cometabolism TetR families controlling gene research of spore
Controlling gene SACE_7040, SACE_0012 and regulation and control erythromycin anabolism gene SACE_5599, SACE_ of state differentiation
3986, SACE_3446, SACE_7301 etc., and it is also unclear for what its precise mechanism for adjusting yield of erythrocin was illustrated.
The content of the invention
The object of the invention is exactly to pass through to lack negative regulator gene SACE_3980 in the red mycete of sugared many spores, many by transforming sugar
The red mycete SACE_3980 genes of spore improve yield of erythrocin method.
The present invention is achieved by the following technical solutions:
It is a kind of to improve yield of erythrocin method by transforming the red mycete SACE_3980 genes of sugared many spores, it is characterised in that:It is logical
Crossing genetic engineering approach makes SACE_3980 gene inactivations in the red mycete of sugared many spores, obtains the red mycete erythromycin high yield work of sugared many spores
Journey bacterial strain, with described strain fermentation production erythromycin.
Described one kind improves yield of erythrocin method, its feature by transforming the red mycete SACE_3980 genes of sugared many spores
It is that described SACE_3980 gene outcomes can be with negative regulation erythromycin biosynthesiss.
Application of the SACE_3980 genes in industrial strain, it is characterised in that:TetR house is lacked in high industrial production bacterial strain
Race open gene SACE_3980, obtains high productive mutant, can be used for erythromycin production.
It is an advantage of the invention that:
Erythromycin biosynthesiss negative regulator SACE_3980 is screened in present invention research, by genetic engineering approach
SACE_3980 gene copies on the red mycete chromosome of sugared many spores are lacked, erythromycin superior strain is obtained in that, is that commercial production is carried
Homoerythromycin fermentation yield provides technical support.
When knocking out SACE_3980 genes in the red mycete A226 of many spores of sugar, yield of erythrocin improves 29.3%, and in Δ
SACE_3980 genes are covered in SACE_3980 deletion mutation strains, yield of erythrocin is restored, and shows that SACE_3980 is one
Participate in the biosynthetic negative regulatory factor of erythromycin.By the use of high industrial production bacterial strain WB as starting strain, lack on its chromosome
SACE_3980 genes are lost, makes yield of erythrocin improve 15.8%, illustrate that lacking SACE_3980 genes improves yield of erythrocin
Technology is equally applicable in high industrial production bacterial strain.
Description of the drawings
Fig. 1:SACE_3980 genes and periphery contiguous gene positional information on chromosome;
Fig. 2:The chromosome segment homologous recombination technique schematic diagram of the present invention and the PCR identifications of deletion mutation strain,
(A) Δ SACE_3980 mutation constructions schematic diagram,
(B) the PCR identifications of Δ SACE_3980 mutants:SACE_3980 genes (639bp) are by tsr resistant genes
(1360bp) after replacing, length is changed into 1727bp;M,5000bp DNA Marker;
Fig. 3:The antibacterial analysis of starting strain A226 and deletion mutation strain Δ SACE_3980 and Erythromycin A output per day point
Analysis,
(A) the antibacterial analysis of A226 starting strains and Δ SACE_3980 mutant fermentation liquids,
(B) the HPLC analyses of six days Erythromycin A products of starting strain A226 and deletion mutation strain Δ SACE_3980;
Fig. 4:The reply of SACE_3980 genes, the structure of overexpression bacterial strain and Erythromycin A volume analyses,
(A) the PCR identifications of A226/pIB139-3980 covering, overexpression bacterial strain:PCR primer is apr resistant genes
(776bp);M, 5000bp DNA Marker,
(B) starting strain A226, deletion mutation strain Δ SACE_3980, disappearance covering bacterial strain and the unloaded control strain of covering,
The HPLC analyses of overexpression bacterium A226/pIB139-3980 and overexpression zero load control strain Erythromycin A;
Fig. 5:The impact of SACE_3980 gene pairss strain morphology differentiation and the measure of Δ SACE_3980 mutant Biomass,
(A) the spore growth situation of Δ SACE_3980 mutants and wild type A226 bacterial strains, wherein 1:A226 bacterial strains, 2:
Δ SACE_3980 mutants, 3:Reply bacterial strain Δ SACE_3980/pIB139-3980,4:Overexpression strains A 226/pIB139-
3980,
(B) Δ SACE_3980 mutants and the mycelial biomass estimation of wild type A226 bacterial strains.
Fig. 6:The structure of erythromycin high industrial production bacterial strain WB/SACE_3980 deletion mutation strains and Erythromycin A volume analyses,
(A) the PCR identifications of WB/ Δs SACE_3980 mutants:SACE_3980 genes (639bp) are by tsr resistant genes
(1360bp) after replacing, length is changed into 1727bp;M, 5000bp DNA Marker,
(B) the HPLC analyses of superior strain WB and deletion mutation strain WB/ Δ SACE_3980 Erythromycin A yield.
Specific embodiment
Embodiment 1
1.1 bacterial strains, plasmid and growth conditionss
Used in test to bacterial strain and plasmid be shown in Table 1.Escherichia coli 37 DEG C LB liquid medium or addition
Cultivate on the solid LB flat boards of 1.25% agar.The red mycete of many spores of erythromycin producing strain sugar and its engineered strain are in 30 DEG C of Trypsins
Peptone soybean broth (TSB) culture medium is cultivated on the R3M flat boards containing 2.2% agar.
1.2 materials, DNA operations and sequencing
PEG3350, lysozyme, TES, casamino acid, thiostrepton, apramycin are bought from Sigma companies.TSB、
Yeast extract, peptone are bought in Oxoid companies.Glycine, agar powder, Sodium Chloride and other biological reagents are all purchased from examination
Agent company.The general operation technology of escherichia coli and the red mycete of sugared many spores is according to standard operation.The synthesis of primer and DNA sequencing by
Sangon Biotech (Shanghai) Co., Ltd. completes.
Strain used and plasmid in the research of table 1
2 present invention of table builds the primer of synthesis
The structure of 1.3 SACE_3980 deletion mutant bodies
The primer sequence synthesized in test is shown in Table 2.PUCTSR plasmids are the BamH I and Sma I restriction enzyme sites in pUC18
Between insert 1360bp thiostrepton resistance gene (tsr).In order to knock out the SACE_3980 bases in the red mycete of sugared many spores
Cause, respectively with 3980-P1/3980-P2 and 3980-P3/3980-P4 be primer, the red mycete A226 genomes of sugared many spores be template,
The homologous fragment of each about 1.5kb in upstream and downstream of PCR amplification SACE_3980 genes.
Above-mentioned two 3980-U and 3980-D upstream and downstream fragments are connected respectively to the tsr resistant gene sequences of pUCTSR respectively
Row both sides, complete to build plasmid pUCTSR Δs 3980;With 3980-P1 and 3980-P4 as primer, 3980 plasmid of pUCTSR Δs is as mould
3980U-tsr-D large fragments are converted by plate, PCR amplification 3980U-tsr-D large fragments using chromosome segment homologous recombination technique
In the red mycete protoplast of many spores of sugar, Positive mutants strain is screened according to thiostrepton resistance, obtain SACE_3980 gene quilts
The engineering strain that tsr is replaced.Using 3980-P5 and 3980-P6 as identification primer, with plasmid pUCTSR Δs 3980 as positive
Template, A226 genomes enter performing PCR identification for negative template, and positive deletion mutant is named as Δ SACE_3980 (see Fig. 3 A).
1.4 SACE_3980 genes reply the structure of bacterial strain
SACE_3980 genes are amplified using the primer 3980-P7 and 3980-P8 of design, and electrophoresis is reclaimed, using NdeI
Double digestion is carried out with pIB139 and is reclaimed with SACE_3980 genetic fragments of the Xba I restriction endonucleases respectively to being recovered to, passed through
T4DNA ligases are connected to SACE_3980 genetic fragments on pIB139, successfully obtain integrative plasmid pIB139-3980.So
PIB139-3980 is imported in Δ SACE_3980 protoplasts by the protoplast transformation method that PEG is mediated afterwards.By peace
General mycin preliminary screening, enters performing PCR identification by object of apramycin resistance gene (apr), and the reply Strain Designation of acquisition is
ΔSACE_3980/pIB139-3980。
Overexpression SACE_3980 genes in 1.5 starting strain A226
The red mycete A226 protoplasts of many spores of protoplast transformation technological sourcing sugar that pIB139-3980 is mediated by PEG
In, enter performing PCR identification by object of apramycin resistance gene (apr), obtain positive strain and be named as A226/pIB139-
3980。
The red mold fermentation product HPLC detections of 1.6 sugared many spores
The red mycete of sugared many spores is inoculated with TSB culture medium, after 30 DEG C of shaken cultivation 48 hours, R5 liquid cultures is forwarded to
Base, 30 DEG C of shaken cultivation 144 hours, is then extracted to fermentation liquid using organic solvent, after being evaporated using water-bath, is added
1mL methanol dissolves and uses 0.22 μm of organic filter membrane to process, and goes up the Erythromycin A content in machine testing sample afterwards.
The red fungal hyphae body Biomass detection of 1.7 sugared many spores
Respectively Δ SACE_3980 mutants are inoculated in the liquid TSB of 30mL with A226 with identical inoculum concentration, 30 DEG C
After shaking table culture 48 hours, 30 DEG C of rotating speed 220rpm shaking table cultures are transferred in R5 culture medium 144 hours, when period arranges different
Between section sampling, weigh dry cell weight with washes of absolute alcohol post-drying, each repeated sampling twice, and obtains meansigma methodss, measures
Fungal biodiversity curve is drawn according to experimental data after end.
The structure of 1.8 erythromycin high industrial production bacterial strain WB/ Δ SACE_3980 bacterial strains and HPLC detections
SACE_3980 is lacked in erythromycin high industrial production bacterial strain WB, verifies that correct Strain Designation is WB/ Δ SACE_
3980.And the tunning by WB superior strains with deletion mutation strain WB/ Δ SACE_3980 carries out HPLC detections.Mutant structure
Process and HPLC detections are built with reference to above-mentioned 1.3 and 1.6 methods.
Interpretation of result:
2.1 deletion mutation strain Δ SACE_3980 are improved compared with starting strain A226 yield of erythrocin.
SACE_3980 is shown in Fig. 1 with position of the gene on the red mycete chromosome of sugared many spores is closed on.SACE_3980 genes lack
Lose mutant A226/ Δ SACE_3980 building processs and see Fig. 2A.SACE_3980 deletion mutants body is containing 30 μ g ml-1
Screen on the R3M flat boards of thiostrepton and confirmed (see Fig. 2 B) by PCR.
Δ SACE_3980 ferments in R5 fluid mediums 6 days (144h), and fermented supernatant fluid is collected by centrifugation;Point sample is in containing
The LB planar surfaces of bacillus subtilises bacterium solution, 37 DEG C culture 12 hours after observe flat board on inhibition zone size, as a result show:Δ
The fermentation liquid inhibition zone of SACE_3980 is compared with A226 substantially (see Fig. 3 A) bigger than normal, preliminary to infer that SACE_3980 genes are probably negative tune
Save the yield in erythromycin.
After fermentation liquid is extracted, Jing HPLC detect daily Erythromycin A yield, it is found that the 6th day Δ SACE_3980 relatively sets out
28.3% (see Fig. 3 B) of the output increased of strains A 226, HPLC results again show that SACE_3980 is that to participate in erythromycin biological
Negative regulation of synthesis.
2.2 SACE_3980 genes are replied and overexpression.
In order to the raising for verifying yield of erythrocin in mutant Δ SACE_3980 is because that SACE_3980 gene delections are drawn
Rise, using SACE_3980 expression vector pIB139-3980 and pIB139 carriers (as control), be directed respectively into Δ SACE_
In the protoplast of 3980 mutants and starting strain A226, obtain and reply bacterial strain and unloaded Δ SACE_3980/pIB139-
3980th, Δ SACE_3980/pIB139, overexpression bacterial strain and zero load A226/pIB139-3980, A226/pIB139, PCR identifications
Confirm (see Fig. 4 A).A226 and Δ SACE_3980 series mutations strain are carried out into shake flask fermentation afterwards, HPLC testing results show:Δ
The Erythromycin A yield of SACE_3980 raises 29.3% compared with A226;Reply the red mould of bacterial strain Δ SACE_3980/pIB139-3980
Plain A yield is recovered substantially compared with A226;The Erythromycin A yield of A226/pIB139-3980 reduces about 20% (see figure compared to A226
4B);HPLC testing results further demonstrate that SACE_3980 genes can bear the biosynthesiss for adjusting Erythromycin A.
2.3 disappearance SACE_3980 gene pairss thalli growths and the impact of spore shape differentiation.
The dry cell weight of the fermentation Δ SACE_3980 mutants of 6 days and A226 bacterial strains is determined, respective change curve is drawn,
As a result show that Δ SACE_3980 is little (see Fig. 5 A) compared with the Biomass difference of A226, implies the disappearance of SACE_3980 genes simultaneously
The primary metabolite of thalline is not affected.
In order to determine whether SACE_3980 genes regulate and control the Sporulation of thalline, by mutant Δ SACE_3980, reply
Bacterial strain Δ SACE_3980/pIB139-3980, overexpression strains A 226/pIB139-3980 and wild type control strain A226
It is applied on R3M flat boards simultaneously, 30 DEG C are cultivated 72 hours, observe bacterial strain spore growth situation.As a result show compared to A226, Δ
The spore shape no significant difference (Fig. 5 B) of SACE_3980 mutants, illustrates that the disappearance of SACE_3980 genes does not affect spore
Formed.
2.4 the high industrial production bacterial strain WB/ Δ SACE_3980 of transformation improve yield of erythrocin.
The structure of WB/ Δ SACE_3980 mutants is carried out first, and building process is shown in Fig. 6 A with reference to Fig. 2A, PCR identifications.Afterwards
WB/ Δ SACE_3980 mutants and high industrial production bacterial strain WB coated plates are activated, shaking for industrial seed culture medium is then respectively connected to
In bottle, after cultivating 2 days under 30 DEG C of rotating speed 220rpm, in switching industrial fermentation culture medium, continue culture 6 days.Extract after fermentation ends
Concentration Jing HPLC analyses are taken, compare starting strain WB, and the yield of erythrocin of WB/ Δ SACE_3980 has been respectively increased 15.8%
(see Fig. 6 B).In this explanation superior strain WB, SACE_3980 genes are also involved in adjusting the yield of erythromycin.
CCCAAGCTTGCGGTGTTCATCAGCGCGAT
GCTCTAGAGCTCGACGAACAGCCGGATG
CGGGGTACCAGATCACCACCGTCCTGCG
CCGGAATTCAGCCTCAACGTGCGGTTCA
GCATGCCACAAAGGCTAACTCGGT
AAGTCAGCACAGGCGTCCTCAGT
GGAATTCCATATGATGGCGGTCATGAGCGAGCC
GCTCTAGATCAGCCGCAGCAGGCGGCC
GGAGTGCATATGGTGCAATACGAATGGCGAAAAG
CTCAAAGCTTCAGCCAATCGACTGGCGAGCG
Claims (3)
1. a kind of by transforming the red mycete of sugared many sporesSACE_3980The method that gene improves yield of erythrocin, it is characterised in that:It is logical
Cross during genetic engineering approach makes the red mycete of sugared many sporesSACE_3980Gene inactivation, obtains the red mycete erythromycin high yield work of sugared many spores
Journey bacterial strain, with described strain fermentation production erythromycin.
2. according to claim 1 a kind of by transforming the red mycete of sugared many sporesSACE_3980Gene improves yield of erythrocin
Method, it is characterised in that it is describedSACE_3980Gene outcome can be with negative regulation erythromycin biosynthesiss.
3.SACE_3980Application of the gene in industrial strain, it is characterised in that:TetR families are lacked in high industrial production bacterial strain
Open geneSACE_3980, high productive mutant is obtained, can be used for erythromycin production.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611146639.6A CN106520866B (en) | 2016-12-13 | 2016-12-13 | Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611146639.6A CN106520866B (en) | 2016-12-13 | 2016-12-13 | Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106520866A true CN106520866A (en) | 2017-03-22 |
CN106520866B CN106520866B (en) | 2021-01-01 |
Family
ID=58342196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611146639.6A Active CN106520866B (en) | 2016-12-13 | 2016-12-13 | Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106520866B (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107881190A (en) * | 2017-11-15 | 2018-04-06 | 安徽大学 | Method for improving lincomycin yield by modifying streptomyces lincolnensis S L CG _2919 gene |
CN109136253A (en) * | 2018-09-28 | 2019-01-04 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _5754 gene approach |
CN109321618A (en) * | 2018-11-13 | 2019-02-12 | 安徽农业大学 | A method of yield of erythrocin is improved by the red mould SACE_5717 gene of the more spores of sugar |
CN110157756A (en) * | 2019-03-11 | 2019-08-23 | 安徽大学 | A method of yield of erythrocin is improved by the red mould SACE_0303 gene of the more spores of transformation sugar |
CN111139192A (en) * | 2019-12-16 | 2020-05-12 | 安徽大学 | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _4682 gene |
CN111363710A (en) * | 2020-03-04 | 2020-07-03 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _4839 gene pathway |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102816814A (en) * | 2012-04-07 | 2012-12-12 | 安徽大学 | Method for improving erythrocin yield through inactivation saccharopolyspora erythraea SACE_3446 gene |
CN103849642A (en) * | 2014-01-13 | 2014-06-11 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _3986 gene |
CN106148378A (en) * | 2016-07-19 | 2016-11-23 | 安徽大学 | Improve yield of erythrocin by sugared many spores red mould SACE_Lrp gene approach |
-
2016
- 2016-12-13 CN CN201611146639.6A patent/CN106520866B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102816814A (en) * | 2012-04-07 | 2012-12-12 | 安徽大学 | Method for improving erythrocin yield through inactivation saccharopolyspora erythraea SACE_3446 gene |
CN103849642A (en) * | 2014-01-13 | 2014-06-11 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _3986 gene |
CN106148378A (en) * | 2016-07-19 | 2016-11-23 | 安徽大学 | Improve yield of erythrocin by sugared many spores red mould SACE_Lrp gene approach |
Non-Patent Citations (1)
Title |
---|
NCBI: "NC_009142.1", 《GENBANK》 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107881190A (en) * | 2017-11-15 | 2018-04-06 | 安徽大学 | Method for improving lincomycin yield by modifying streptomyces lincolnensis S L CG _2919 gene |
CN107881190B (en) * | 2017-11-15 | 2021-02-09 | 安徽大学 | Method for improving lincomycin yield by modifying streptomyces lincolnensis SLCG _2919 gene |
CN109136253A (en) * | 2018-09-28 | 2019-01-04 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _5754 gene approach |
CN109136253B (en) * | 2018-09-28 | 2021-08-10 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _5754 gene approach |
CN109321618A (en) * | 2018-11-13 | 2019-02-12 | 安徽农业大学 | A method of yield of erythrocin is improved by the red mould SACE_5717 gene of the more spores of sugar |
CN109321618B (en) * | 2018-11-13 | 2021-06-18 | 安徽农业大学 | Method for improving erythromycin yield through saccharopolyspora erythraea SACE _5717 gene |
CN110157756A (en) * | 2019-03-11 | 2019-08-23 | 安徽大学 | A method of yield of erythrocin is improved by the red mould SACE_0303 gene of the more spores of transformation sugar |
CN110157756B (en) * | 2019-03-11 | 2022-03-29 | 安徽大学 | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _0303 gene |
CN111139192A (en) * | 2019-12-16 | 2020-05-12 | 安徽大学 | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _4682 gene |
CN111139192B (en) * | 2019-12-16 | 2022-04-15 | 安徽大学 | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _4682 gene |
CN111363710A (en) * | 2020-03-04 | 2020-07-03 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _4839 gene pathway |
CN111363710B (en) * | 2020-03-04 | 2022-02-18 | 安徽大学 | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _4839 gene pathway |
Also Published As
Publication number | Publication date |
---|---|
CN106520866B (en) | 2021-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106520866A (en) | Method for improving yield of erythromycin by modifying saccharopolyspora erythraea SACE _3980 gene | |
Luo et al. | Activation and characterization of a cryptic polycyclic tetramate macrolactam biosynthetic gene cluster | |
CN107881190B (en) | Method for improving lincomycin yield by modifying streptomyces lincolnensis SLCG _2919 gene | |
CN110157756B (en) | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _0303 gene | |
JP6882330B2 (en) | Carrimycin biosynthetic gene cluster | |
CN103849642B (en) | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _3986 gene | |
Yu et al. | Genome shuffling of Streptomyces roseosporus for improving daptomycin production | |
Li et al. | Biosynthesis and molecular regulation of secondary metabolites in microorganisms | |
CN102816814A (en) | Method for improving erythrocin yield through inactivation saccharopolyspora erythraea SACE_3446 gene | |
WO2019214347A1 (en) | Genetic screening method for negative regulatory factor of streptomyces biosynthesis gene cluster | |
CN112251456B (en) | Method for improving lincomycin yield through streptomyces lincolnensis regulation gene combination modification | |
CN109136253A (en) | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _5754 gene approach | |
CN110484481A (en) | A method of lincomycin yield is improved by transformation Str. lincolnensis SLCG_3128 gene | |
CN103205451B (en) | Yield of erythrocin is improved by the many spores of sugar red mould SACE_7301 gene approach | |
CN109321618B (en) | Method for improving erythromycin yield through saccharopolyspora erythraea SACE _5717 gene | |
CN106148378A (en) | Improve yield of erythrocin by sugared many spores red mould SACE_Lrp gene approach | |
CN111139192B (en) | Method for improving erythromycin yield by modifying saccharopolyspora erythraea SACE _4682 gene | |
Pinjari et al. | Detection and expression of biosynthetic gene clusters in actinobacteria | |
WO2019223433A1 (en) | Genetically engineered bacterium of fidaxomicin and construction method and application thereof | |
CN103361345B (en) | The biosynthetic method of the biological components and parts strengthening secondary metabolite of restructuring regulation and control | |
CN111363710B (en) | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _4839 gene pathway | |
CN111197019B (en) | Method for improving yield of erythromycin through saccharopolyspora erythraea SACE _1906 gene approach | |
CN105316383B (en) | A method of improving the oxytetracycline yield of streptomycete by gene disruption | |
CN106190854B (en) | A kind of preparation method of desert pseudocyst bacterium and oritavancin intermediate | |
CN117904162A (en) | Method for improving erythromycin yield by modifying rhodosporidium saccharatum SACE_5680 gene and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |